SS-31: The Mitochondria-Targeting Peptide for Ener…

SS-31, also known by its clinical name Elamipretide, is a tetrapeptide that selectively accumulates in the inner mitochondrial membrane where it interacts with cardiolipin—a critical phospholipid that maintains mitochondrial structure and function. It is one of the most advanced mitochondria-targeted therapeutics in clinical development and has attracted enormous interest in both aging research and cardiovascular medicine.

The Mitochondrial Connection to Aging

Mitochondria are often described as the cellular powerhouses, but they are also primary sites of reactive oxygen species (ROS) production. As mitochondria age, their membranes deteriorate, electron transport chain efficiency declines, and ROS production increases. This creates a self-reinforcing cycle: damaged mitochondria produce more oxidative stress, which further damages mitochondrial membranes.

The result is declining ATP production, increased cellular senescence, and the progressive functional decline we recognize as aging. This mitochondrial dysfunction is now considered one of the central hallmarks of aging and a driver of virtually every age-related disease.

How SS-31 Targets Cardiolipin

SS-31's unique mechanism centers on cardiolipin, a phospholipid found almost exclusively in the inner mitochondrial membrane. Cardiolipin plays structural roles in maintaining cristae architecture and functional roles in supporting the electron transport chain complexes. With aging and oxidative stress, cardiolipin becomes oxidized and its function deteriorates.

SS-31 binds directly to cardiolipin, preventing its oxidation and stabilizing the mitochondrial membrane architecture. This allows electron transport chain complexes to maintain their efficiency, reducing electron leak (which generates ROS) and preserving ATP production capacity. The peptide essentially acts as a molecular stabilizer for aging mitochondria.

Clinical Evidence: Heart Failure and Ischemia

SS-31/Elamipretide has completed Phase II clinical trials for heart failure with preserved ejection fraction (HFpEF)—one of the most difficult-to-treat cardiac conditions. In a 28-day trial, SS-31 produced significant improvements in exercise tolerance and quality of life measures, with a favorable safety profile.

In animal models of myocardial infarction and ischemia-reperfusion injury, SS-31 dramatically reduced cardiac cell death and preserved heart function. Its ability to protect mitochondria during the metabolic stress of ischemia makes it highly relevant for cardiac medicine.

Energy, Exercise Capacity, and Aging

Research in aged animals shows SS-31 improves exercise capacity by restoring mitochondrial efficiency in skeletal muscle. Older animals treated with SS-31 demonstrate improved running endurance, faster muscle recovery, and better maintenance of muscle mass—effects that parallel what is observed when mitochondrial function is artificially enhanced in experimental models.

In aged humans, skeletal muscle mitochondrial function is a primary determinant of exercise capacity and independence. This positions SS-31 as one of the most mechanistically relevant anti-aging compounds for maintaining physical function into late life.

Neuroprotective Applications

Neuronal cells are particularly dependent on mitochondrial health due to their extremely high energy demands. SS-31 has shown neuroprotective effects in models of Alzheimer's disease, Parkinson's disease, and stroke. It reduces mitochondrial dysfunction in neurons, lowers beta-amyloid toxicity, and improves neuronal survival under stress conditions.

As the scientific understanding of these neurodegenerative diseases increasingly centers on mitochondrial dysfunction as an upstream driver, SS-31 has attracted attention as a potential disease-modifying therapy.

Kidney Protection and Metabolic Benefits

Beyond cardiac and neural applications, SS-31 has demonstrated protection against kidney ischemia-reperfusion injury, diabetic nephropathy, and contrast-induced nephropathy. Kidney cells, like neurons and cardiomyocytes, have extremely high mitochondrial density and are particularly vulnerable to mitochondrial dysfunction.

Metabolic benefits observed in research models include improved insulin sensitivity and glucose metabolism—consistent with the role of skeletal muscle mitochondrial health in whole-body metabolic regulation.

FAQ

Q: How does SS-31 differ from conventional antioxidants? A: SS-31 targets cardiolipin in the inner mitochondrial membrane directly, preventing oxidative damage at the source rather than scavenging free radicals after they are produced.

Q: Is SS-31 available for human use? A: Elamipretide is in clinical trials; it is available as a research peptide from specialized suppliers but is not FDA-approved for general use.

Q: What dose of SS-31 is used in research protocols? A: Clinical trials have used subcutaneous injections of 0.25–40 mg/m2; research peptide protocols vary widely and lack standardized human dosing.

Q: Can SS-31 be combined with other mitochondrial support compounds? A: Yes, it is often studied alongside compounds like NAD+ precursors and CoQ10 for synergistic mitochondrial support.

Track your supplements in Optimize.

SS-31: The Mitochondria-Targeting Peptide for Energy and Longevity